Search
New at EHA 15: EHA-JSH Joint Symposium
On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".
Read moreThe European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO
The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).
Read moreCME-European Accreditors: A New European CME/CPD Association
A new association of accrediting boards in Continuing Medical Education/Continuing Professional Development in Europe has been established.
Read moreEuropean Hematology Association publishes new journal with Wolters Kluwer
The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.
Read moreTraining vital for new era of patient-centric healthcare
Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…
Read moreIn Memoriam Pieter Van Vlierberghe
We are deeply saddened to announce that Pieter Van Vlierberghe (42) has passed away.
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read moreGdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
EHA reaffirms commitment to hematology's future with new brand identity
The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.
Read more